An Open-label Phase 2 Study to Evaluate the Safety and Immnogenicity of a Single Subcutaneous Injection of Quadrivalent TAK-850 in Healthy Adult Subjects

Status: Withdrawn prior to enrolment

Phase of Trial: Phase II

Latest Information Update: 01 Sep 2016

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs TAK 850 (Primary)
Indications Influenza A virus infections; Influenza B virus infections; Influenza virus infections
Focus Adverse reactions; Pharmacodynamics
Sponsors Takeda

24 Aug 2016 Status changed from active, no longer recruiting to withdrawn prior to enrolment.
22 Apr 2016 Status changed from not yet recruiting to active, no longer recruiting.
22 Mar 2016 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com